CD44s Expression and Lung Cancer Outcomes
Author Information
Author(s): Ko Yoon Ho, Won Hye Sung, Jeon Eun Kyoung, Hong Sook Hee, Roh Sang Young, Hong Young Seon, Byun Jae Ho, Jung Chan-Kwon, Kang Jin Hyoung
Primary Institution: Catholic University, South Korea
Hypothesis
Is CD44s expression involved in the clinical outcomes of patients with resected non-small cell lung cancer (NSCLC)?
Conclusion
High CD44s expression is a negative prognostic marker in patients with resected NSCLC, especially those with adenocarcinoma histology.
Supporting Evidence
- High CD44s expression was found in 91.7% of squamous cell carcinoma patients compared to 53.2% in adenocarcinoma patients.
- High CD44s expression correlated with advanced lymph node metastasis.
- In multivariate analysis, high CD44s expression was a significant predictor of survival in adenocarcinoma patients.
Takeaway
This study found that patients with high levels of a protein called CD44s in their lung cancer tissue tend to have worse outcomes, especially if they have a specific type of lung cancer called adenocarcinoma.
Methodology
Immunohistochemical staining was used to analyze CD44s expression in tissue samples from 159 NSCLC patients.
Potential Biases
Potential selection bias due to the study being conducted at a single institution.
Limitations
The study is retrospective and conducted at a single institution, which may introduce selection bias.
Participant Demographics
The cohort included 123 males and 36 females, with a median age of 64 years.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI, 2.222-12.226
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website